LEO Pharma

New General Manager appointed to lead LEO Pharma across the Nordic region

Del

Klaus Abel arrives to take the regional helm of the global medical dermatology leader

April 30, Malmo, Sweden: LEO Pharma, a global leader in medical dermatology, has appointed Klaus Abel to take the helm as Managing Director for the Nordics.

Klaus Abel moves into the new role from Lundbeck where he was for 19 years. While at Lundbeck, he held senior roles in Global Marketing and in Commercial Operations in addition to Managing Director positions in Australia/New Zealand from 2007-2011 and Italy from 2016-2018.  In his new position, Klaus will report to Geraldine Murphy, Regional Vice President Cluster North Europe, Australia & New Zealand, LEO Pharma.

I am delighted to be taking charge of LEO Pharma in the Nordics at this exciting time for the organisation. I was attracted to LEO Pharma by its high ambitions, pioneering approach and clear focus on patients. Being a foundation-owned company LEO Pharma has no shareholders and is committed to reinvesting its profits into R&D. These aspects really stand out to me. I am inspired by the opportunity to improve the quality of life of the many people living with skin conditions by engaging all the stakeholders involved in providing care for people suffering from skin disease ranging from patients, policy makers, and healthcare professionals”, said Klaus Abel, Managing Director, LEO Pharma Nordics.

In terms of his approach to his new role, Klaus Abel added, “The organisation has declared its intent to help 125 million patients by 2025. It is an ambitious goal and I look forward to addressing the challenges ahead in bringing that strategy and vision to fruition. I intend to help build a best in class organisation and by increasing collaboration, championing cross functional collaboration in a true multi-channel integration to communication.

As Managing Director for the Nordics Organisation Klaus Abel will lead operations in Denmark, Sweden, Norway , Finland and Iceland. He will be responsible for driving LEO Pharma’s Dermatology business, developing talent and ensuring a successful implementation of LEO Pharma’s 2025 strategy. Klaus will also be part of the Cluster Europe North Australia New Zealand Leadership team.

Geraldine Murphy added, “It is a real pleasure to welcome Klaus Abel to LEO Pharma and the Cluster Leadership team. We very much look forward to working with him going forward to achieve our 2025 goals. We have a fantastic opportunity to draw on Klaus’s extensive knowledge and share experiences between our Cluster countries and collaborate closely together to be the preferred dermatology care partner. Our whole team is committed to helping people achieve healthy skin”.

Kontakter

For further information please contact the Communications team:

Julie Wong, Head of Communications, LEO Pharma UK

T: +44 (0)7825918989 E: comms@leo-pharma.com

Billeder

Information om LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million. For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com

LEO Pharma Nordics is headquartered in Malmo, Sweden and comprises 55 people conducting commercial operations across both Dermatology and Thrombosis. The team spans Norway, Denmark, Sweden, Finland and Iceland and also has offices in Helsinki and Oslo.

For more information on careers within LEO Pharma Nordics please contact Lars Skouboe, Senior People Partner, E: LQUDK@leo-pharma.com

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management10.5.2019 10:27:35 CESTPressemeddelelse

Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.

New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CESTPressemeddelelse

Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.

LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology9.4.2019 10:00:56 CESTPressemeddelelse

Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.

LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment19.3.2019 10:33:23 CETPressemeddelelse

Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum